Sorafenib (NEXAVAR) is a multitargeted inhibitor of VEGF, PDGFR, and RAF kinase that has been approved in the USA and EU for HCC (hepatocellular carcinoma) and advanced RCC (61). Here, VEGFA is linked to renal cell adenocarcinoma.